53 research outputs found
Análise de Custo-Efetividade do Monitoramento da Insuficiência CardÃaca pelo proBNP comparado ao Monitoramento ClÃnico
Fundamento: Inexiste atualmente um guia prático para orientar a intensidade do tratamento farmacológico de pacientes com insuficiência cardÃaca (IC) crônica. Objetivo: Verificar se a farmacoterapia orientada pelas concentraçoes da fraçao amino-terminal do pro-BNP (proBNP) resulta em melhor desfecho e menor custo se comparada ao monitoramento clÃnico isolado, em pacientes com IC crônica. Métodos: Para a análise de custo-efetividade foi utilizada uma árvore de decisao modelada para o cenário do Sistema Suplementar de Saúde Brasileiro. Foram utilizados dados de efetividade publicados em ensaio clÃnico controlado e randomizado (ECCR) e dados de custos do tratamento obtidos de estudos brasileiros sobre epidemiologia e custos da IC. Foram contabilizados custos diretos com hospitalizaçoes, atendimentos de urgência, consultas, medicamentos ambulatoriais, exames complementares e valor do teste do proBNP, em um perÃodo de 12 meses. A unidade de efetividade avaliada fo
Análise de Custo-Efetividade do Monitoramento da Insuficiência CardÃaca pelo proBNP comparado ao Monitoramento ClÃnico
Fundamento: Inexiste atualmente um guia prático para orientar a intensidade do tratamento farmacológico de pacientes com insuficiência cardÃaca (IC) crônica. Objetivo: Verificar se a farmacoterapia orientada pelas concentraçoes da fraçao amino-terminal do pro-BNP (proBNP) resulta em melhor desfecho e menor custo se comparada ao monitoramento clÃnico isolado, em pacientes com IC crônica. Métodos: Para a análise de custo-efetividade foi utilizada uma árvore de decisao modelada para o cenário do Sistema Suplementar de Saúde Brasileiro. Foram utilizados dados de efetividade publicados em ensaio clÃnico controlado e randomizado (ECCR) e dados de custos do tratamento obtidos de estudos brasileiros sobre epidemiologia e custos da IC. Foram contabilizados custos diretos com hospitalizaçoes, atendimentos de urgência, consultas, medicamentos ambulatoriais, exames complementares e valor do teste do proBNP, em um perÃodo de 12 meses. A unidade de efetividade avaliada fo
Indications and practical approach to non-invasive ventilation in acute heart failure
In acute heart failure (AHF) syndromes significant respiratory failure (RF) is essentially seen in patients with acute cardiogenic pulmonary oedema (ACPE) or cardiogenic shock (CS). Non-invasive ventilation (NIV), the application of positive intrathoracic pressure through an interface, has shown to be useful in the treatment of moderate to severe RF in several scenarios. There are two main modalities of NIV: continuous positive airway pressure (CPAP) and pressure support ventilation (NIPSV) with positive end expiratory pressure. Appropriate equipment and experience is needed for NIPSV, whereas CPAP may be administered without a ventilator, not requiring special training. Both modalities have shown to be effective in ACPE, by a reduction of respiratory distress and the endotracheal intubation rate compared to conventional oxygen therapy, but the impact on mortality is less conclusive. Non-invasive ventilation is also indicated in patients with AHF associated to pulmonary disease and may be considered, after haemodynamic stabilization, in some patients with CS. There are no differences in the outcomes in the studies comparing both techniques, but CPAP is a simpler technique that may be preferred in low-equipped areas like the pre-hospital setting, while NIPSV may be preferable in patients with significant hypercapnia. The new modality 'high-flow nasal cannula' seems promising in cases of AHF with less severe RF. The correct selection of patients and interfaces, early application of the technique, the achievement of a good synchrony between patients and the ventilator avoiding excessive leakage, close monitoring, proactive management, and in some cases mild sedation, may warrant the success of the technique
Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC)Â of the European Society of Cardiology.
The current European Society of Cardiology (ESC) Heart Failure Guidelines are the most comprehensive ESC document covering heart failure to date; however, the section focused on acute heart failure remains relatively too concise. Although several topics are more extensively covered than in previous versions, including some specific therapies, monitoring and disposition in the hospital, and the management of cardiogenic shock, the lack of high-quality evidence in acute, emergency, and critical care scenarios, poses a challenge for providing evidence-based recommendations, in particular when by comparison the data for chronic heart failure is so extensive. The paucity of evidence and specific recommendations for the general approach and management of acute heart failure in the emergency department is particularly relevant, because this is the setting where most acute heart failure patients are initially diagnosed and stabilized. The clinical phenotypes proposed are comprehensive, clinically relevant and with minimal overlap, whilst providing additional opportunity for discussion around respiratory failure and hypoperfusion.F.P. has received research grants from
Abbott, Becton Dickenson, Brainbox, Calcimedica, CSL Behring,
Cue, Ortho Clinical Diagnostics, Relypsa, Roche, Salix, Siemens.
Consultant: Abbott, Astra-Zeneca, Beckman, Bosch, Fast Biomedical,
Forrest Devices, Ischemia Care, Dx, Instrument Labs, Janssen,
Nabriva, Ortho Clinical Diagnostics, Osler, Relypsa, Roche, Quidel,
Salix, Siemens, Upstream and has stock/ownership interests in
AseptiScope Inc, Brainbox Inc, Braincheck Inc, Coagulo Inc,
Comprehensive Research Associates LLC, Comprehensive Research
Management Inc, Emergencies in Medicine LLC, Fast Inc, Forrest
Devices, Ischemia DX LLC, Lucia Inc, Prevencio Inc, ScPharma,
Trivirum Inc, Upstream Inc. E.P.’ employer has received support from
Novartis for consulting work and she has consulted for
scPharmaceuticals outside of the submitted work. She has received
research support from the NIH (R01HL148439).S
Incremental value of B-type natriuretic peptide for early risk prediction of infective endocarditis
SummaryBackgroundEarly and accurate risk prediction is an unmet clinical need in patients with infective endocarditis (IE). The aim of this study was to determine the value of B-type natriuretic peptide (BNP) levels obtained on admission for the prediction of in-hospital death in IE patients.MethodsBetween 2009 and 2011, consecutive patients with IE diagnosed using the revised Duke criteria and admitted to the emergency department were evaluated prospectively. BNP levels were measured on admission. Death during hospitalization was the primary endpoint.ResultsAmong 104 consecutive patients with IE and with available BNP levels, 34 (32.7%) died in hospital. BNP levels were significantly higher in patients who died as compared to survivors (709.0 pg/ml vs. 177.5 pg/ml, p<0.001). The accuracy of BNP to predict death as quantified by the area under the receiver operating characteristics curve was 0.826 (95% confidence interval (CI) 0.747–0.905). The value of BNP was additive to that provided by clinical, microbiological, and echocardiography assessment. On multivariate analysis, new heart failure (hazard ratio (HR) 2.02, 95% CI 1.15–3.57, p=0.015), sepsis (HR 2.10, 95% CI 1.25–3.55, p=0.005), Staphylococcus aureus endocarditis (HR 2.67, 95% CI 1.60–4.45, p<0.001), left ventricular ejection fraction ≤55% (HR 1.63, 95% CI 1.00–2.65, p=0.047), and BNP (HR 1.04, 95% CI 1.02–1.06, p<0.001) were independent predictors of in-hospital mortality.ConclusionAmong patients with IE, BNP levels obtained on admission provide incremental value for early and accurate risk prediction
Biomarkers for prediction of mortality in left-sided infective endocarditis
Background: Evidence regarding biomarkers for risk prediction in patients with infective endocarditis (IE) is limited. We aimed to investigate the value of a panel of biomarkers for the prediction of in-hospital mortality in patients with IE. Methods: Between 2016 and 2018, consecutive IE patients admitted to the emergency department were prospectively included. Blood concentrations of nine biomarkers were measured at admission (D0) and on the seventh day (D7) of antibiotic therapy: C-reactive protein (CRP), sensitive troponin I (s-cTnI), procalcitonin, B-type natriuretic peptide (BNP), neutrophil gelatinase-associated lipocalin (NGAL), interleukin 6 (IL6), tumor necrosis factor α (TNF-α), proadrenomedullin, alpha-1-acid glycoprotein, and galectin 3. The primary endpoint was in-hospital mortality. Results: Among 97 patients, 56% underwent cardiac surgery, and in-hospital mortality was 27%. At admission, six biomarkers were independent predictors of in-hospital mortality: s-cTnI (OR 3.4; 95%CI 1.8–6.4; P < 0.001), BNP (OR 2.7; 95%CI 1.4–5.1; P = 0.002), IL-6 (OR 2.06; 95%CI 1.3–3.7; P = 0.019), procalcitonin (OR 1.9; 95%CI 1.1–3.2; P = 0.018), TNF-α (OR 1.8; 95%CI 1.1–2.9; P = 0.019), and CRP (OR 1.8; 95%CI 1.0–3.3; P = 0.037). At admission, S-cTnI provided the highest accuracy for predicting mortality (area under the ROC curve: s-cTnI 0.812, BNP 0.727, IL-6 0.734, procalcitonin 0.684, TNF-α 0.675, CRP 0.670). After 7 days of antibiotic therapy, BNP and inflammatory biomarkers improved their performance (s-cTnI 0.814, BNP 0.823, IL-6 0.695, procalcitonin 0.802, TNF-α 0.554, CRP 0.759). Conclusion: S-cTnI concentration measured at admission had the highest accuracy for mortality prediction in patients with IE
Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024
Hypertrophic cardiomyopathy (HCM) is a form of genetically caused heart muscle disease, characterized by the thickening of the ventricular walls. Diagnosis requires detection through imaging methods (Echocardiogram or Cardiac Magnetic Resonance) showing any segment of the left ventricular wall with a thickness > 15 mm, without any other probable cause. Genetic analysis allows the identification of mutations in genes encoding different structures of the sarcomere responsible for the development of HCM in about 60% of cases, enabling screening of family members and genetic counseling, as an important part of patient and family management. Several concepts about HCM have recently been reviewed, including its prevalence of 1 in 250 individuals, hence not a rare but rather underdiagnosed disease. The vast majority of patients are asymptomatic. In symptomatic cases, obstruction of the left ventricular outflow tract (LVOT) is the primary disorder responsible for symptoms, and its presence should be investigated in all cases. In those where resting echocardiogram or Valsalva maneuver does not detect significant intraventricular gradient (> 30 mmHg), they should undergo stress echocardiography to detect LVOT obstruction. Patients with limiting symptoms and severe LVOT obstruction, refractory to beta-blockers and verapamil, should receive septal reduction therapies or use new drugs inhibiting cardiac myosin. Finally, appropriately identified patients at increased risk of sudden death may receive prophylactic measure with implantable cardioverter-defibrillator (ICD) implantation.La miocardiopatÃa hipertrófica (MCH) es una forma de enfermedad cardÃaca de origen genético, caracterizada por el engrosamiento de las paredes ventriculares. El diagnóstico requiere la detección mediante métodos de imagen (Ecocardiograma o Resonancia Magnética CardÃaca) que muestren algún segmento de la pared ventricular izquierda con un grosor > 15 mm, sin otra causa probable. El análisis genético permite identificar mutaciones en genes que codifican diferentes estructuras del sarcómero responsables del desarrollo de la MCH en aproximadamente el 60% de los casos, lo que permite el tamizaje de familiares y el asesoramiento genético, como parte importante del manejo de pacientes y familiares. Varios conceptos sobre la MCH han sido revisados recientemente, incluida su prevalencia de 1 entre 250 individuos, por lo tanto, no es una enfermedad rara, sino subdiagnosticada. La gran mayorÃa de los pacientes son asintomáticos. En los casos sintomáticos, la obstrucción del tracto de salida ventricular izquierdo (TSVI) es el trastorno principal responsable de los sÃntomas, y su presencia debe investigarse en todos los casos. En aquellos en los que el ecocardiograma en reposo o la maniobra de Valsalva no detecta un gradiente intraventricular significativo (> 30 mmHg), deben someterse a ecocardiografÃa de esfuerzo para detectar la obstrucción del TSVI. Los pacientes con sÃntomas limitantes y obstrucción grave del TSVI, refractarios al uso de betabloqueantes y verapamilo, deben recibir terapias de reducción septal o usar nuevos medicamentos inhibidores de la miosina cardÃaca. Finalmente, los pacientes adecuadamente identificados con un riesgo aumentado de muerte súbita pueden recibir medidas profilácticas con el implante de un cardioversor-desfibrilador implantable (CDI).A cardiomiopatia hipertrófica (CMH) é uma forma de doença do músculo cardÃaco de causa genética, caracterizada pela hipertrofia das paredes ventriculares. O diagnóstico requer detecção por métodos de imagem (Ecocardiograma ou Ressonância Magnética CardÃaca) de qualquer segmento da parede do ventrÃculo esquerdo com espessura > 15 mm, sem outra causa provável. A análise genética permite identificar mutações de genes codificantes de diferentes estruturas do sarcômero responsáveis pelo desenvolvimento da CMH em cerca de 60% dos casos, permitindo o rastreio de familiares e aconselhamento genético, como parte importante do manejo dos pacientes e familiares. Vários conceitos sobre a CMH foram recentemente revistos, incluindo sua prevalência de 1 em 250 indivÃduos, não sendo, portanto, uma doença rara, mas subdiagnosticada. A vasta maioria dos pacientes é assintomática. Naqueles sintomáticos, a obstrução do trato de saÃda do ventrÃculo esquerdo (OTSVE) é o principal distúrbio responsável pelos sintomas, devendo-se investigar a sua presença em todos os casos. Naqueles em que o ecocardiograma em repouso ou com Manobra de Valsalva não detecta gradiente intraventricular significativo (> 30 mmHg), devem ser submetidos à ecocardiografia com esforço fÃsico para detecção da OTSVE. Pacientes com sintomas limitantes e grave OTSVE, refratários ao uso de betabloqueadores e verapamil, devem receber terapias de redução septal ou uso de novas drogas inibidoras da miosina cardÃaca. Por fim, os pacientes adequadamente identificados com risco aumentado de morta súbita podem receber medida profilática com implante de cardiodesfibrilador implantável (CDI)
- …